<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Janumet(TM,) a fixed dose combination of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, that are inadequately controlled, either by <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> or <z:chebi fb="0" ids="6801">metformin</z:chebi> alone or together in free-dose combination form </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi>, an inhibitor of the enzyme DDP-4, assists patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> to achieve glycemic control </plain></SENT>
<SENT sid="2" pm="."><plain>It has been shown to be safe and effective at 100 mg daily doses </plain></SENT>
<SENT sid="3" pm="."><plain>The effect of giving <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> is thought to have a complimentary and possibly additive effect on glycemic control </plain></SENT>
</text></document>